Price Target Estimates for Flexion Therapeutics, Inc. (FLXN)

The FDA on Friday backed Flexion's Zilretta to treat osteoarthritic knee pain

The FDA on Friday backed Flexion's Zilretta to treat osteoarthritic knee pain

Cantor Fitzgerald set a $40.00 price objective on Flexion Therapeutics and gave the stock a "buy" rating in a research note on Monday, June 12th.

03/23/2017 - Flexion Therapeutics Inc had its "outperform" rating reiterated by analysts at Wells Fargo. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned "Buy" rating by RBC Capital Markets on Monday, September 11. Company shares last traded at $27.17 barely above $24.92, the 50 day moving average and much higher than the 200 day moving average of $22.59. The company now has an average rating of "Buy" and an average target price of $29.23.

Taking a broader look at the analyst consensus, according to 9 analysts Flexion Therapeutics (NASDAQ:FLXN)'s price will reach at $37.44 during 52 weeks. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company's stock valued at $54,921,000 after acquiring an additional 591,981 shares during the period.

The company is now down by 3.79%% since yesterday's close of 28.24. Comparatively, Flexion Therapeutics, Inc. posted earnings of $-0.82 per share in the same quarter past year. 6,500,996 shares of the stock traded hands. The stock's 52-week range is $15.93 to $32.25, and its 3-month range is $ to $. The stock's last price was higher from the average trading price of 50 days recorded at $24 while enlarging the period to 200 trading days, the average price was $21.66. The company has market cap of $868.80 million. Analysts expect next quarter's EPS will be $-1.13 with next year's EPS projected to be $-3.40. Equities research analysts predict that Flexion Therapeutics will post ($3.75) EPS for the current year.

Facebook confirms Russian Federation ads on Instagram
The source said Google is still sorting out whether some of the ads came from legitimate Russian accounts. Last week, Facebook handed some 3,000 ads over to federal lawmakers investigating Russian interference.

In other Flexion Therapeutics news, insider Neil Bodick sold 5,000 shares of the stock in a transaction on Monday, April 17th. The stock presently has a consensus rating of "Buy" and an average price target of $34.67. Technical analysts have little regard for the value of a company. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The stock was sold at an average price of $23.00, for a total value of $69,000.00. The disclosure for this sale can be found here. Analysts are forecasting earnings of $-0.95 on a per share basis this quarter. Insiders have purchased 5,375 shares of company stock valued at $131,575 in the last 90 days. The company's price to sales ratio for trailing twelve months is 0.65 and price to book ratio for most recent quarter is 2.15, whereas price to cash per share for the most recent quarter is 12.30. Schwab Charles Investment Management Inc. grew its holdings in shares of Flexion Therapeutics by 0.5% during the second quarter. Russell Investments Group Ltd. acquired a new stake in Flexion Therapeutics during the fourth quarter worth $715,000. This is not a recommendation to buy or sell Flexion Therapeutics, Inc.

11/26/2014 - Flexion Therapeutics Inc had its "hold" rating reiterated by analysts at Summer Street. This no-warrant financing will be the largest capital raise - at the highest price per share - in the history of 22nd Century and will raise the Company's cash balance to well over $60 million - enough to meet all regular operating expenses for more than five years.

Flexion Therapeutics, Inc.is a United States specialty pharmaceutical company. The Firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The Business's lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain.

Latest News